Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review

Hydration Requirements with Emetogenic Chemotherapy: Granisetron Extended-Release Subcutaneous Versus Palonosetron

“…Suboptimal control of CINV increases resource utilization, including CINV-related office visits and hospital and emergency room visits [10]. In a systematic literature review, all economic studies reviewed were in agreement that poorly controlled CINV remains a problem, leading to increases in both direct costs (e.g., clinic, hospital and emergency room visits; rescue medication) and indirect costs (e.g., patient work days lost) [7]. A recent retrospective analysis of data from US Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project website reported that there were 37,730 hospital discharges for nausea and vomiting in 2014, with mean charges of $23,603 per visit, including both hospital costs and physician fees [22].…”

“…A recent retrospective analysis of data from US Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project website reported that there were 37,730 hospital discharges for nausea and vomiting in 2014, with mean charges of $23,603 per visit, including both hospital costs and physician fees [22]. Furthermore, failure to control CINV also has a considerable negative effect on patients' quality of life, even in patients receiving MEC, highlighting the need for early and effective CINV prevention [7]. The reductions in the number of hydration events with GERSC compared with palonosetron, observed in the current analysis, would be expected to be associated with reduced healthcare costs for hydration for patients who received GERSC as the 5-HT 3 receptor antagonist in a three-drug antiemetic regimen, compared with patients who received palonosetron.…”

“…Poorly controlled chemotherapy-induced nausea and vomiting (CINV) negatively affects patient health, quality of life and chemotherapy compliance [1][2][3][4][5][6][7], and is associated with increased resource utilization and healthcare costs [7][8][9][10]. Despite comprehensive antiemetic treatment guidelines [11][12][13][14], there is still an unmet clinical need to improve the prevention of CINV.…”

Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study

“…CINV has a negative impact on the life quality of patients by further diminishing cancer treatment adherence (Sommariva, Pongiglione, & Tarricone, 2016; Tageja & Groninger, 2016). Failing adequate antiemetic treatment, more than 90% of patients experience CINV due to highly emetogenic chemotherapy (HEC) (Hesketh, 2008).…”

An Analysis of Behavioral and Genetic Risk Factors for Chemotherapy-Induced Nausea and Vomiting in Japanese Subjects

“…Inadequately controlled emesis impairs functional activity and QOL for patients, increases the use of health care resources, and may occasionally compromise adherence to treatment. 1,2) According to the American Society of Clinical Oncology Clinical Practice Guidelines regarding antiemetic agents in oncology, a three-drug combination of a serotonin 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonist, dexamethasone, and aprepitant is recommended before chemotherapy treatments that have high emetic risks. If this is insufficient, substituting a high-dose of intravenous metoclopramide for the serotonin 5-HT 3 receptor antagonist or adding a dopamine D 2 receptor antagonist to the regimen is considered.…”